The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates

Authors

Natalie I. Mazur, Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, Netherlands; Department of Paediatrics, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, Netherlands.
Deborah Higgins, Center for Vaccine Innovation and Access, PATH, Seattle, WA, USA.
Marta C. Nunes, Medical Research Council: Respiratory and Meningeal Pathogens Research Unit and Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, Johannesburg, South Africa; Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands.
José A. Melero, Centro Nacional de Microbiología and CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III Majadahonda, Madrid, Spain.
Annefleur C. Langedijk, Department of Paediatrics, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, Netherlands.
Nicole Horsley, Department of Biology, University of Washington, Seattle, WA, USA.
Ursula J. Buchholz, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Peter J. Openshaw, National Heart and Lung Institute, Faculty of Medicine, Imperial College, London, UK.
Jason S. McLellan, Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Janet A. Englund, Department of Pediatrics, University of Washington, Seattle, WA, USA; Seattle Children's Research Institute, Seattle, WA, USA.
Asuncion Mejias, Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Department of Pediatrics, Division of Infectious Diseases, Center for Vaccines and Immunity at Nationwide Children's Hospital, The Ohio State University, Columbus, OH, USA; Departamento de Farmacología y Pediatria, Facultad de Medicina, Universidad de Malaga, Malaga, Spain.
Ruth A. Karron, Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Eric Af Simões, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA; Department of Epidemiology Center for Global Health, Colorado School of Public Health, Aurora, CO, USA.
Ivana Knezevic, Norms and Standards for Biologicals, Department of Essential Medicines and Health Products, World Health Organization, Geneva, Switzerland.
Octavio Ramilo, Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Department of Pediatrics, Division of Infectious Diseases, Center for Vaccines and Immunity at Nationwide Children's Hospital, The Ohio State University, Columbus, OH, USA.
Pedro A. Piedra, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA; Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA; Department of Molecular Virology and Microbiology, and Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Helen Y. Chu, Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands.
Ann R. Falsey, Rochester Regional HealthFollow
Harish Nair, Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK.
Leyla Kragten-Tabatabaie, Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Julius Clinical, Zeist, Netherlands.
Anne Greenough, Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; MRC-Asthma UK Centre in Allergic Mechanisms of Asthma, School of Life Course Sciences, King's College London, London, UK.
Eugenio Baraldi, Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Women's and Children's Health Department, University of Padova, Padova, Italy.
Nikolaos G. Papadopoulos, Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Allergy Department, 2nd Paediatric Clinic, National Kapodistrian University of Athens, Athens, Greece; Division of Infection, Immunity & Respiratory Medicine, University of Manchester, Manchester, UK.
Johan Vekemans, Initiative for Vaccine Research, World Health Organization, Geneva, Switzerland.
Fernando P. Polack, Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Fundacion INFANT, Buenos Aires, Argentina.
Mair Powell, Licensing Division, Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK.
Ashish Satav, Mahatma Gandhi Tribal Hospital, Karmagram, Utavali, Tahsil, Dharni, India.
Edward E. Walsh, Rochester Regional HealthFollow
Renato T. Stein, Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands; Pontificia Universidade Católica RGS (PUCRS), Porto Alegre, Brazil.
Barney S. Graham, Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Louis J. Bont, Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, Netherlands; Department of Paediatrics, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, Netherlands; Respiratory Syncytial Virus Network (ReSViNET) Foundation, Zeist, Netherlands.

Department

Infectious Diseases

Document Type

Article

Publication Title

The Lancet. Infectious Diseases

Abstract

The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by providing a new target for preventive interventions. The RSV vaccine landscape has rapidly expanded to include 19 vaccine candidates and monoclonal antibodies (mAbs) in clinical trials, reflecting the urgency of reducing this global health problem and hence the prioritisation of RSV vaccine development. The candidates include mAbs and vaccines using four approaches: (1) particle-based, (2) live-attenuated or chimeric, (3) subunit, (4) vector-based. Late-phase RSV vaccine trial failures highlight gaps in knowledge regarding immunological protection and provide lessons for future development. In this Review, we highlight promising new approaches for RSV vaccine design and provide a comprehensive overview of RSV vaccine candidates and mAbs in clinical development to prevent one of the most common and severe infectious diseases in young children and older adults worldwide.

First Page

e295

Last Page

e311

DOI

10.1016/S1473-3099(18)30292-5

Volume

18

Issue

10

Publication Date

10-1-2018

Medical Subject Headings

Antibodies, Monoclonal (immunology); Antibodies, Viral (immunology); Global Health; Humans; Nanoparticles; Respiratory Syncytial Virus Infections (prevention & control); Respiratory Syncytial Virus Vaccines (immunology); World Health Organization

PubMed ID

29914800

Recommended Citation

Mazur, N. I., Higgins, D., Nunes, M. C., Melero, J. A., Langedijk, A. C., Horsley, N., Buchholz, U. J., Openshaw, P. J., McLellan, J. S., Englund, J. A., Mejias, A., Karron, R. A., Simões, E. A., Knezevic, I., Ramilo, O., Piedra, P. A., Chu, H. Y., Falsey, A. R., Nair, H., Kragten-Tabatabaie, L., Greenough, A., Baraldi, E., Papadopoulos, N. G., Vekemans, J., Polack, F. P., Powell, M., Satav, A., Walsh, E. E., Stein, R. T., Graham, B. S., & Bont, L. J. (2018). The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. The Lancet. Infectious Diseases, 18 (10), e295-e311. https://doi.org/10.1016/S1473-3099(18)30292-5